{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:15:59Z","timestamp":1739510159915,"version":"3.37.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008501","name":"East Carolina University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Adjuvant chemotherapy is recommended as an option for patients who have high-risk features. It remains unclear whether all patients with high-risk stage II colon cancer benefit from adjuvant therapy. The primary aim of this study is to evaluate the association between adjuvant chemotherapy and overall survival in patients with high-risk stage II colon cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Utilizing the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2019, adult patients with high-risk stage II colon cancer defined as T4 tumor classification, perineural invasion, less than 12 lymph nodes harvested, and poorly differentiated histology. 1:1 ratio propensity matching was used to adjust for confounding variables. Survival differences based on receipt of adjuvant systemic therapy were summarized using a log rank test. Cox proportion hazard regression was used to evaluate overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 11,619 patients who met inclusion criteria, 2775 (24%) received adjuvant chemotherapy. Patients were more likely to receive adjuvant therapy if they were younger, married or partnered, or had left-sided lesions. Kaplan\u2013Meier estimates showed an improvement in overall survival (log-rank test\u2009&lt;\u20090.001). On pair-stratified Cox proportional hazards regression, adjuvant chemotherapy receipt was associated with 30% lower mortality hazard (hazard ratio [HR] 0.70; 95% CI 0.62, 0.80; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). However, on landmark analysis, after excluding patients surviving\u2009&lt;\u20093\u00a0months, adjuvant chemotherapy was no longer associated with mortality hazard (HR 0.90; 95% CI 0.79, 1.04; <jats:italic>p<\/jats:italic>\u2009=\u20090.144).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings from this large SEER database study provide support for not undergoing adjuvant chemotherapy to patients with high-risk stage II colon cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12029-025-01186-z","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:39:49Z","timestamp":1739443189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Chemotherapy for High-Risk Stage II Colon Cancer: A Population-Based Study"],"prefix":"10.1007","volume":"56","author":[{"given":"Annmarie","family":"Butare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tia","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Kantzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie N.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Tumin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4574-2094","authenticated-orcid":false,"given":"Michael D.","family":"Honaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"1186_CR1","unstructured":"Colorectal cancer \u2014 cancer stat facts. NIH National Cancer Institute, Surveillance Epidemiology and End Results Program Web site. https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html. Accessed Jul 16, 2024."},{"issue":"8","key":"1186_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40(8):892\u2013910. https:\/\/doi.org\/10.1200\/JCO.21.02538. Accessed Jul 16, 2024.","journal-title":"J Clin Oncol"},{"key":"1186_CR3","unstructured":"U.S. Cancer Statistics Working Group. United states cancer statistics: data visualizations. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute Web site. https:\/\/www.cdc.gov\/cancer\/dataviz. Updated 2024. Accessed 7\/16, 2024."},{"key":"1186_CR4","doi-asserted-by":"publisher","first-page":"755113","DOI":"10.3389\/fonc.2021.755113","volume":"11","author":"A Mohamed","year":"2021","unstructured":"Mohamed A, Jiang R, Philip PA, et al. High-risk features are prognostic in dMMR\/MSI-H stage II colon cancer. Front Oncol. 2021;11:755113. https:\/\/doi.org\/10.3389\/fonc.2021.755113 https:\/\/pubmed.ncbi.nlm.nih.gov\/34760701\/. Accessed Sep 9, 2024.","journal-title":"Front Oncol"},{"key":"1186_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12957-024-03405-6","volume":"22","author":"C Chu","year":"2024","unstructured":"Chu C, Lai I, Jong B, et al. The prognostic and predictive significance of perineural invasion in stage I to III colon cancer: a propensity score matching-based analysis. World J Surg Oncol. 2024;22:129. https:\/\/doi.org\/10.1186\/s12957-024-03405-6 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11088143\/. Accessed Sep 9, 2024.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1186_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/cncr.29072","volume":"121","author":"A Kumar","year":"2015","unstructured":"Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121(4):527\u201334. https:\/\/doi.org\/10.1002\/cncr.29072. Accessed Jul 16, 2024.","journal-title":"Cancer"},{"issue":"8","key":"1186_CR7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/DCR.0000000000002425","volume":"66","author":"LN Hajirawala","year":"2023","unstructured":"Hajirawala LN, Yi Y, Herritt BC, et al. Multiple high-risk features for stage II colon carcinoma portends worse survival than stage III disease. Dis Colon Rectum. 2023;66(8):1076\u201384. https:\/\/doi.org\/10.1097\/DCR.0000000000002425. Accessed Jul 16, 2024","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"1186_CR8","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479\u2013516. https:\/\/doi.org\/10.1093\/annonc\/mds236. Accessed Jul 16, 2024.","journal-title":"Ann Oncol"},{"issue":"4","key":"1186_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/JOP.2016.017210","volume":"13","author":"J Kannarkatt","year":"2017","unstructured":"Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13(4):233\u201341. https:\/\/doi.org\/10.1200\/JOP.2016.017210. Accessed Jul 16, 2024.","journal-title":"J Oncol Pract"},{"key":"1186_CR10","unstructured":"NCCN guidelines - version 4, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed July 16, 2024."},{"key":"1186_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jss.2020.02.016","volume":"252","author":"N Enofe","year":"2020","unstructured":"Enofe N, Morris AD, Liu Y, et al. Receipt of adjuvant chemotherapy in stage II colon cancer and overall survival: a national cancer database study. J Surg Res. 2020;252:69\u201379. https:\/\/doi.org\/10.1016\/j.jss.2020.02.016 https:\/\/pubmed.ncbi.nlm.nih.gov\/32244127\/. Accessed Sep 9, 2024.","journal-title":"J Surg Res"},{"issue":"1","key":"1186_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00384-023-04581-9","volume":"39","author":"P Zheng","year":"2023","unstructured":"Zheng P, Ye C, Liu H, Gao X, Huang H. Adjuvant chemotherapy decision-making in stage II colon adenocarcinoma associated with patients\u2019 age and high-risk factors. Int J Colorectal Dis. 2023;39(1):3. https:\/\/doi.org\/10.1007\/s00384-023-04581-9 https:\/\/pubmed.ncbi.nlm.nih.gov\/38091096\/. Accessed Sep 9, 2024.","journal-title":"Int J Colorectal Dis"},{"issue":"11","key":"1186_CR13","doi-asserted-by":"publisher","first-page":"e78709","DOI":"10.1371\/journal.pone.0078709","volume":"8","author":"Y Lee","year":"2013","unstructured":"Lee Y, Lee Y, Chuang J, Lee J. Differences in survival between colon and rectal cancer from SEER data. PLoS One. 2013;8(11):e78709. https:\/\/doi.org\/10.1371\/journal.pone.0078709 https:\/\/pubmed.ncbi.nlm.nih.gov\/24265711\/. Accessed Dec 11, 2024.","journal-title":"PLoS One"},{"key":"1186_CR14","unstructured":"Overview of the SEER program. National Cancer Institute: Surveillance, Epidemiology, and End Results Program Web site. https:\/\/seer.cancer.gov\/about\/overview.html. Accessed Dec 11, 2024."},{"key":"1186_CR15","unstructured":"Surveillance, epidemiology, and end results (SEER) program (www.seer.cancer.gov) SEER*Stat database: Incidence - incidence-SEER research plus data, 17 registries, nov 2021 sub (2000\u20132019) - linked to county attributes - time dependent (1990\u20132019) income\/rurality, 1969\u20132020 counties, national cancer institute, DCCPS, surveillance research program, released april 2022, based on the november 2021 submission."},{"key":"1186_CR16","unstructured":"World Health Organization. International classification of diseases for oncology, 3rd edition (ICD-O-3). https:\/\/www.who.int\/standards\/classifications\/other-classifications\/international-classification-of-diseases-for-oncology. Updated 2024."},{"issue":"4","key":"1186_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"1186_CR18","unstructured":"Block S, Office of Information and Regulatory Affairs, Office of Management and Budget, Executive Office of the President. 2020 standards for delineating core based statistical areas. https:\/\/www.federalregister.gov\/documents\/2021\/07\/16\/2021-15159\/2020-standards-for-delineating-core-based-statistical-areas."},{"issue":"9","key":"1186_CR19","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1080\/0284186X.2023.2251086","volume":"62","author":"V Rosberg","year":"2023","unstructured":"Rosberg V, Jessen M, Qvortrup C, Smith HG, Krarup P. Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study. Acta Oncol. 2023;62(9):1076\u201382. https:\/\/doi.org\/10.1080\/0284186X.2023.2251086. Accessed Jul 16, 2024.","journal-title":"Acta Oncol"},{"key":"1186_CR20","doi-asserted-by":"publisher","first-page":"175628482211377","DOI":"10.1177\/17562848221137758","volume":"15","author":"L Liu","year":"2022","unstructured":"Liu L, Xiang Z. Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study. Therap Adv Gastroenterol. 2022;15:17562848221137758. https:\/\/doi.org\/10.1177\/17562848221137758. Accessed Jul 16, 2024.","journal-title":"Therap Adv Gastroenterol"},{"issue":"23","key":"1186_CR21","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709. Accessed Jul 16, 2024.","journal-title":"N Engl J Med"},{"issue":"9604","key":"1186_CR22","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(07)61866-2. Accessed Jul 16, 2024.","journal-title":"Lancet"},{"issue":"6","key":"1186_CR23","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1245\/s10434-023-13340-7","volume":"30","author":"MD Honaker","year":"2023","unstructured":"Honaker MD, Irish W, Parikh AA, Snyder RA. Association of rural residence and receipt of guideline-concordant care for locoregional colon cancer. Ann Surg Oncol. 2023;30(6):3538\u201346. https:\/\/doi.org\/10.1245\/s10434-023-13340-7 https:\/\/pubmed.ncbi.nlm.nih.gov\/36933082\/. Accessed Sep 9, 2024.","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"1186_CR24","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/cncr.32118","volume":"125","author":"HG Lyu","year":"2019","unstructured":"Lyu HG, Haider AH, Landman AB, Raut CP. The opportunities and shortcomings of using big data and national databases for sarcoma research. Cancer. 2019;125(17):2926\u201334. https:\/\/doi.org\/10.1002\/cncr.32118 https:\/\/pubmed.ncbi.nlm.nih.gov\/31090929\/. Accessed Sep 9, 2024.","journal-title":"Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01186-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01186-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01186-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:39:56Z","timestamp":1739443196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01186-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01186-z","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"63"}}